| Year | Month | History |
|---|---|---|
| 2018 | Oct. | FUJIFILM RI Pharma merged TOYAMA CHEMICAL. Company name changed to FUJIFILM Toyama Chemical Co., Ltd. |
| 2019 | Jan. | Launch of medication verification system "PROOFIT 1D" |
| 2019 | Feb. | Launch of ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan |
| 2019 | Dec. | Completion of manufacturing facility for liposome formulations in Toyama Second Factory |
| 2021 | Feb. | Approval of PEMETREXED INTRAVENOUS INFUSION 100mg/500mg "TOWA" |
| 2021 | Apr. | Transfer of rights to IOPROMIDE Injection and IOPROMIDE Injection Syringe to Bayer Yakuhin, Ltd. in Japan |
| 2021 | Jun. | Approval of LUTATHERA® Ingection and LYSAKARE® Injection |
| 2021 | Jul. | Succession of the constant-temperature transportation device business to TOHO PHARMACEUTICAL CO., LTD. |
| 2021 | Sep. | Approval of Raiatt MIBG-I 131 Injection |
| 2021 | Nov. | Transfer of marketing rights for ORAVI® Mucoadhesive Tablets 50mg to Hisamitsu Pharmaceutical |
| 2022 | Mar. | Succession of the radiopharmaceutical business to PDRadiopharma Inc. |
TOYAMA CHEMICAL Co., Ltd.
| Year | History |
|---|---|
| 1936 | Toyama Chemical Co., Ltd., established around the business of Toyama Chemical Research Laboratory |
| 1961 | Head office relocated from Toyama to Nihonbashi, Tokyo |
| Listed on the second section of the Tokyo Stock Exchange | |
| 1970 | General Research Laboratory completed |
| 1971 | Factory for the manufacture of injectable products completed |
| 1972 | Listed on the first section of the Tokyo Stock Exchange |
| First phase of pharmaceutical factory completed | |
| 1975 | No. 2 Research Laboratory completed |
| Second phase of pharmaceutical factory completed | |
| 1978 | Head office relocated from Nihonbashi to Shinjuku, Tokyo |
| 1979 | Approval of PENTCILLIN injection and intramuscular |
| 1980 | No. 3 Research Laboratory completed |
| 1981 | Approval of ABOVIS capsules Toyama Second Factory established |
| 1982 | Approval of BAXO capsules |
| 1985 | No. 5 Research Laboratory completed |
| 1986 | Approval of BAXO ointment |
| 1987 | Approval of TOMIRON tablet |
| 1988 | Approval of BAXO suppositories |
| 1989 | No. 1 Research Laboratory completed |
| 1990 | Approval of OZEX tablet |
| Approval of TOMIRON fine granules | |
| 1998 | Pharmaceutical factory and distribution wing completed |
| 1999 | LUPRAC tablet introduced in Japan |
| 2002 | HALOSPOR intravenous introduced in Japan |
| Agreed on a strategic capital and business alliance with Taisho Pharmaceutical Co., Ltd. | |
| Approval of PASIL intravenous drip | |
| Taisho Toyama Pharmaceutical Co., Ltd. established | |
| Approval of PENTCILLIN intravenous bag | |
| 2006 | Approval of OZEX ophthalmic solution |
| No. 6 Research Laboratory completed | |
| 2007 | Approval of GENINAX tablet |
| 2008 | Agreed on a strategic capital and business alliance between FUJIFILM Holdings Corporation, Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd. |
| Delisted on the first section of the Tokyo Stock Exchange | |
| Approval of ZOSYN intravenous | |
| 2009 | Approval of OZEX fine granules |
| 2012 | No. 7 Research Laboratory completed |
| Approval of KOLBET tablet | |
| 2013 | Factory for the manufacture of injectable products completed |
| 2014 | Factory for the manufacture of injectable bag products completed |
| Approval of AVIGAN tablet | |
| Approval of ZOSYN intravenous bag | |
| 2018 | Transfer of rights to KOLBET tablet to Eisai Co., Ltd. in Japan |
| Toyama Chemical Co., Ltd. became 100% subsidiary of FUJIFILM Corporation |